An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.
The FDA has approved tirzepatide – which will be sold under the brand name Zepbound – to treat overweight and obesity. It’s the latest entrant into a field of powerful new drugs that includes Ozempic and Wegovy.
An enzyme called PGK1 has an unexpectedly critical role in the production of chemical energy in brain cells, according to a preclinical study led by researchers at Weill Cornell Medicine.
Weill Cornell Medicine is collaborating with colleagues in Tanzania to increase the pipeline of female doctors, researchers and policymakers in health care, and focus attention on women’s health in Tanzania.
Researchers have uncovered DNA markers associated with retroelements, remnants of ancient viral genetic material, in our genes that act as highly accurate epigenetic clocks predicting chronological age.
A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease.
A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.
A decline in estrogen during menopause causes changes in body fat distribution and associated cardiovascular and metabolic disease, but a new Cornell-led study identifies potential therapies that might one day reverse these unhealthy shifts.
